43077-09-4

Upstream product

• 1389323-90-3 C₂₂H₂₄N₆O₆ 
• 676-58-4 methylmagnesium chloride 
• 1581768-74-2 C₂₀H₁₈N₅O₆^(1-)*Na⁽¹⁺⁾ 
• 19234-66-3 2',3'-isopropylideneadenosine-5'-carboxylic acid 
• 75-16-1 methylmagnesium bromide 
• 98-88-4 benzoyl chloride 

Downstream Products

• 68224-54-4 N-(9-((3aR,4R,6R,6aR)-6-((S)-1-hydroxyethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide 
• 35868-16-7 (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((S)-1-hydroxyethyl)tetrahydrofuran-3,4-diol 
• 3253-81-4 (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((R)-1-hydroxyethyl)tetrahydrofuran-3,4-diol 

Relevant academic research and scientific papers

SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Preparation of both C5′ epimers of 5′- C -methyladenosine: Reagent control trumps substrate control

Adenosine-derived ketone 5 was subjected to Noyori asymmetric transfer hydrogenation (ATH) using aqueous sodium formate as a stoichiometric reductant. Despite the well-known sensitivity of ATH to stereoelectronic effects from a contiguous stereogenic center, the 5′ stereochemistry was overwhelmingly controlled by the chirality of the catalyst. Both the (5′S,4′R) and the (5′R,4′R) diastereomers could be prepared selectively in good yields. An efficient three-step route that provides ketone 5 in 75% overall yield was developed.